|
Jun 07, 2013
|
|
17:16
|
| Pankaj Patel, Chairman and Managing Director, Zydus Cadila |
| India Infoline Research Team/17:16,Jun 07,2013 |
| We are targeting Lipaglyn sales of 100 crore in the next 3-5 years. |
|
|
Jun 03, 2013
|
|
18:00
|
| Ipca Laboratories (Q4 FY13) |
| India Infoline Research Team/18:00,Jun 03,2013 |
| Ipca Labs reported numbers are well in line with our estimates. The company reported revenue growth of 19.7% yoy to Rs6.7bn vs. estimated revenue at Rs6.8bn. |
|
|
May 30, 2013
|
|
11:23
|
| Cipla (Q4 FY13) |
| India Infoline Research Team/11:23,May 30,2013 |
| We believe with changing business model which is visible from of Medpro acquisition, growth is inevitable. We maintain our BUY rating with a target price to Rs463. |
|
|
May 22, 2013
|
|
14:51
|
| Apollo Hospitals (Q4 FY13) |
| India Infoline Research Team/14:51,May 22,2013 |
| The growth in hospital segment was muted due to extended weekend holidays during the quarter leading to lower inpatient volumes. |
|
|
May 15, 2013
|
|
11:05
|
| Dr Reddy’s (Q4 FY13) |
| India Infoline Research Team/11:05,May 15,2013 |
| Revenue growth of 25.6% yoy to Rs33.4bn was ahead of our expectation by 10%. Revenues from Global Generics segment grew by 22.7% yoy to Rs22.6bn, wherein North America grew by 30.7% even on a higher base of last year and Europe was flat. |
|
|
May 10, 2013
|
|
16:04
|
| Ranbaxy Laboratories (Q1 CY13) |
| India Infoline Research Team/16:04,May 10,2013 |
| Overall, sales grew in most emerging markets including India (+11%), EU, CIS (+23.3%), Africa and Middle East (+22.4%) |
|
|
May 09, 2013
|
|
18:06
|
| Glenmark Pharmaceuticals (Q4 FY13) |
| India Infoline Research Team/18:06,May 09,2013 |
| Amongst geographies in specialty segment, India registered strong growth of 32.4% and led most of the out-performance, Latin America revenues grew by 4.7% and Europe climbed up by 25.2% after registering weak performance in last quarter. RoW also continued its strong performance (+21.1%). API segment reported growth of 10.4% yoy to Rs939mn. |
|
|
|
|
14:28
|
| Talwalkars Better Value Fitness (Q4 FY13) |
| India Infoline Research Team/14:28,May 09,2013 |
| PAT jumped 27% yoy led by robust EBIDTA growth (+33% yoy) and lower interest costs (-24.6% yoy) due to better treasury management and deployment of QIP funds to reduce interest expenses |
|
|
May 02, 2013
|
|
13:12
|
| Planning Personal Finance? How assured are you? |
| Neeraj Basur/13:12,May 02,2013 |
| If you think you have rightly planned your personal finance, check where does medical emergencies fit into it |
|
|
Apr 30, 2013
|
|
13:11
|
| Rajesh Srivastava, CMD, Rockland Group of Hospitals |
| India Infoline Research Team/13:11,Apr 30,2013 |
| Rajesh Srivastava says, In India the mindset is changing from ‘sick care’ to ‘healthcare and therefore propelling a huge demand in quality healthcare services. Rockland Hospitals is looking at equity dilution. |
|
|
Apr 29, 2013
|
|
16:40
|
| Planning Personal Finance? How assured are you? |
| Neeraj Basur//16:40,Apr 29,2013 |
| If you think you have rightly planned your personal finance, check where does medical emergencies fit into it. |
|
|
Apr 23, 2013
|
|
14:07
|
| Dr Vyanketesh Joshi, MD, SDF Holistic Healthcare & Research Centre |
| India Infoline Research Team/14:07,Apr 23,2013 |
| We have six centers in Mumbai i.e. Borivali, Goregaon, Vile Parle, Dadar, Thane and Dombivali. We intend to open one center in each district of India. We aspire to be the best known brand in the area of alternative healing in the country. |
|
|
Apr 09, 2013
|
|
14:21
|
| Control your Blood Pressure |
| A. N. Khan/14:21,Apr 09,2013 |
| The heart is a wonderful organ, working day and night, without rest, beating approximately 70 times/ minute, 100,000 times/day. It drives the blood through thousands of km blood vessels to nourish each and every cell in our body. |
|
|
Apr 03, 2013
|
|
14:25
|
| Pranav Anam, CEO, EmProcell Clinical Research |
| Sudhir Raikar/14:25,Apr 03,2013 |
| Pranav Anam, CEO, EmProcell Clinical Research (www.emprocell.com) shared his thoughts on the evolving paradigms in Stem cell research and application. Excerpts of the interaction with Sudhir Raikar… |
|
|
Mar 29, 2013
|
|
12:59
|
| USFDA lifts the import alert on Unit VI of Aurobindo Pharma |
| India Infoline Research Team/12:59,Mar 29,2013 |
| APL, in the past one year has witnessed many highs and lows led by USFDA clearance uncertainties and setbacks at the operational front. |
|
|
Mar 21, 2013
|
|
15:48
|
| Ranbaxy: Set to get back lost sheen |
| India Infoline Research Team/15:48,Mar 21,2013 |
| Ranbaxy has a rich pipeline of Para-IV filings. We expect sustainable cash-flows from these products till CY15. The company had over 40% market share in Lipitor, ahead of street estimates but batch recall put a pause to its growth. |
|
|
Feb 25, 2013
|
|
14:47
|
| Are you at risk of computer injury? |
| India Infoline News Service/14:47,Feb 25,2013 |
| "Motion is the lotion for our joints. Movement and activity circulate joint fluid and promotes cartilage health and bone strength. Too much sitting with poor posture for more than four hours daily can indeed lead to degenerative joint process which affects knees, hips and spine, “says Dr Rajeev K Sharma, Senior Consultant Orthopedic & Joint Replacement Surgeon at Indraprastha Apollo Hospital, New Delhi. |
|
|
|
|
11:15
|
| Dr. Habil Khorakiwala, Founder Chairman & Group CEO, Wockhardt Limited |
| Yash Ved/11:15,Feb 25,2013 |
| “The India business grew by 14% and the Emerging markets business grew by 18% compared to the corresponding quarter of Financial Year 2011-12.” |
|
|
Feb 15, 2013
|
|
12:23
|
| Dr Reddy's (Q3 FY13) |
| India Infoline Research Team/12:23,Feb 15,2013 |
| We revise our 9-month target price to Rs2,080 and maintain our BUY rating |
|
|
Feb 14, 2013
|
|
14:29
|
| Dheeraj Aggarwal, CFO, Venus Remedies Ltd |
| Anil Mascarenhas and Yash Ved/14:29,Feb 14,2013 |
| “Over the next 3years, we plan to increase R&D share of revenue at 45-50%.” |
|